Shares of Navidea Biopharmaceuticals (NYSE: NAVB) fell out of bed mid-day Wednesday despite winning FDA approval for Lymphoseek ahead of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE